参考文献/References:
[1] 〖ZK(#〗Sverden E,BrusselaersN,WahlinK,et al.Time latencies of Helicobacter pylori eradication after peptic ulcer and risk of recurrent ulcer,ulcer adverse events,and gastric cancer:a populationbased cohort study[J].Gastrointest Endosc,2018,88(2):242250.
[2] 肖怀芳,赵西位,黄定桂,等.HP感染与不同类型上消化道疾病的相关性及感染危险因素分析[J].中华医院感染学杂志,2016,26(14):31903192.
[3] 蔡 晋.消化性溃疡临床特点及复发原因分析[J].中国煤炭工业医学杂志,2017,20(1):2729.
[4] 赖人旭,任江南,苟新敏,等.铝碳酸镁片联合埃索美拉唑肠溶片治疗幽门螺杆菌感染合并活动性胃溃疡的临床研究[J].中国临床药理学杂志,2017,33(19):18681870.
[5] 刘爱萍.加味乌贝散治疗胃溃疡临床疗效[J].陕西中医,2017,38(3):314315.
[6] 张艳梅,胡玢婕,赵付菊,等.幽门螺杆菌的耐药性及其相关耐药基因的分析[J].检验医学,2016,31(5):412418.
[7] Beckman E,SaracinoI,FioriniG,et al.A novel stool PCR test for helicobacter pylori may predict clarithromycin resistance and eradication of infection at a high rate[J].J Clin Microbiol,2017,55(8):24002405.
[8] 郝小鹰,刘 溯,李兴华,等.安胃汤加减联合常规西医治疗胃溃疡的疗效观察[J].陕西中医,2016,37(7):864866.〖JP〗
[9] Fu W,Song Z,Zhou L,et al.Randomizedclinical trial:esomeprazole,bismuth,levofloxacin,and amoxicillin or cefuroxime as firstLine eradication regimens for helicobacter pylori infection[J].Dig Dis Sci,2017,62(6):15801589.〖ZK)〗
[10] 〖ZK(#〗Mori H,Suzuki H,Matsuzaki J,et al.Antibiotic resistance and gyrA mutation affect the efficacy of 10day sitafloxacinmetronidazoleesomeprazole therapy for Helicobacter pylori in penicillin allergic patients[J].United European Gastroenterol J,2017,5(6):796804.
[11] 高淑娟,高银虎,许君望.埃索美拉唑与奥美拉唑治疗幽门螺杆菌相关性胃溃疡82例[J].陕西医学杂志,2017,46(9):12841286.
[12] 王瑞芳.埃索美拉唑治疗老年胃溃疡的HP根除效果及对MMP、TIMP1表达的影响[J].现代医学,2016,44(9):12631266.
[13] 卢万可,宋 辉,陶伍元.埃索美拉唑联合抗菌药物治疗十二指肠溃疡临床观察[J].西北药学杂志,2016,31(4):419421.